

OMICS GROUP

OMICS Group International through its Open Access Initiative is committed to make genuine and reliable contributions to the scientific community. OMICS Group hosts over **400** leading-edge peer reviewed Open Access Journals and organizes over **300** International Conferences annually all over the world. OMICS Publishing Group journals have over **3 million** readers and the fame and success of the same can be attributed to the strong editorial board which contains over **30000** eminent personalities that ensure a rapid, quality and quick review process. OMICS Group signed an agreement with more than **1000** International Societies to make healthcare information Open Access.

OMICS Journals are welcoming Submissions

OMICS Group welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best possible way. OMICS Journals are poised in excellence by publishing high quality research. OMICS Group follows an Editorial Manager® System peer review process and boasts of a strong and active editorial board.

Editors and reviewers are experts in their field and provide anonymous, unbiased and detailed reviews of all submissions. The journal gives the options of multiple language translations for all the articles and all archived articles are available in HTML, XML, PDF and audio formats. Also, all the published articles are archived in repositories and indexing services like DOAJ, CAS, Google Scholar, Scientific Commons, Index Copernicus, EBSCO, HINARI and GALE.

For more details please visit our website: http://omicsonline.org/Submitmanuscript.php





ISSN: 2165-7920

Review in 3 weeks

Publishing in 72 hours

Open Access

 During School of Medicine, at National Autonomous University of Mexico (UNAM), I obtained training in vascular physiology.

Pergamon

Life Sciences, Vol. 57, No. 5, pp. 473-486, 1995 Copyright © 1995 Elsevier Science Ltd Printed in the USA. All rights reserved 0024-3205/95 \$9 50 + .00

0024-3205(95)00281-2

EFFECTS OF ACUTE AND CHRONIC ESTROGENIC TREATMENT ON VASOMOTOR RESPONSES OF AORTIC RINGS FROM OVARIECTOMIZED RATS

M.C. Paredes-Carbajal, M.A. Juárez-Oropeza*, C.M. Ortíz-Mendoza and D. Mascher

Department of Physiology and *Department of Biochemistry, School of Medicine, U.N.A.M., P.O. Box 70-250, Mexico D.F. 04510, MEXICO

(Received in final form May 8, 1995)





Publishing in 72 hours

Open Access

ISSN: 2165-7920

• In General Surgery, I combined my experience in basic physiology with hepatic diseases in my thesis "role of endothelium in vascular reactivity alterations induced by jaundice of extrabiliary hepatic obstructive origin: an experimental model."



UNIYERSIDAD NACIONAL AUTONOMA DE MEXICO FACULTAD DE MEDICINA HOSPITAL GENERAL DE MEXICO SECRETARIA DE SALUD

SERVICIO DE CIRUGIA GENERAL

PAPEL DEL ENDOTELIO EN LAS ALTERACIONES DE LA REACTIVIDAD VASCULAR INDUCIDAS POR LA ICTERICIA DE ORIGEN OBSTRUCTIVO BILIAR EXTRAHEPATICO: UN MODELO EXPERIMENTAL EN RATA. ENTRE EREIGI E MEDIA MANSED EXCIDINICIÓN TESSI S ENTRE EREIGI E MEDIA MANSED EXCIDINICIÓN TESSI S ENTRE EREIGI E MEDIA MANSED EXCIDINICIÓN TESSI S ELEMENTA: DR. CARLOS MANUEL [ORTIZ MENDOZA

> DIRECTOR DE TISIS: DR. DIETER MASCHER GRAMLICH

MEXICO, D. F.





ISSN: 2165-7920

Review in 3 weeks

Publishing in 72 hours

Open Access

 During Surgical Oncology training, I performed research on complications of advanced locally cervical cancer induced bv radiotherapy.

ARTÍCULO ORIGINAL



Uso de sulfóxido de dimetilo intravesical como tratamiento para la cistitis hemorrágica posterior a radioterapia

Carlos Manuel Ortíz-Mendoza,* Laura Suchil-Bernal,** Adela Poitevin-Chacón,*** Pedro Martínez-Cervera,* Marco Antonio Aragón-Castro,* Miguel Ángel Jiménez-Ríos*

RESUMEN

Introducción. El sulfóxido de dimetilo es útil como tratamiento para la cistitis intersticial, sin embargo, no existen reportes sobre su empleo en la cistitis hemorrágica postradioterapia (CHPR). Material y métodos. En este trabajo se analiza la experiencia en 51 pacientes con CHPR tratados con sulfóxido de dimetilo intravesical, entre 1996 y 1999 en el Servicio de Urología del Instituto Nacional de Cancerología. Resultados. El sulfóxido demostró utilidad para control de la fase aguda de la CHPR en 86.3% de los pacientes: No se registraron eventos adversos atribuibles al medicamento. Conclusión. De acuerdo con nuestros resultados, el sulfóxido de dimetilo es una alternativa accesible y segura en estos casos.

Palabras clave: Cistitis hemorrágica postradioterapia, sulfóxido de dimetilo, hematuria, complicaciones de radioterapia.

ABSTRACT

Basic research interest

PRÁCTICA CLÍNICO-QUIRÚRGICA

Aportaciones originales

surgical • As a oncologist at Hospital General Tacuba, ISSSTE, dependent of the Mexican Government, my main research areas are breast, cervical, and

endometrial cancers.

¹Carlos Manuel Ortiz-Mendoza, ²Norma Alicia Acosta-Sánchez

Ganglios en histerectomía por cáncer cervical.

¹Servicio de Oncología Quirúrgica ²Servicio de Anatomía Patológica

Hospital General Tacuba, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Distrito Federal, México

Comunicación con: Carlos Manuel Ortiz-Mendoza Tel y fax: (55) 5265 2949 Correo electrónico: cortizmendoza@yahoo.com.mx

La obesidad: principal factor de riesgo para cáncer de endometrio

Carlos Manuel Ortiz-Mendoza,ª Claudia Velasco-Navarro

In México, la obesidad se ha incrementado hasta afectar al 30 % de la población.¹² En coneste trastorno (cáncer, diabetes, hipertensión, etcétera) han aumentado.²⁴

Entre las neoplasias malignas se encuentra el cáncer de endometrio, el cual tiene como factor de reigopo reconocido a la obesidad.⁹ Hay reportes de regiones de Europa en donde, con el incremento de la población obesa, también aumentaron los casos y la mortalidad a causa de este cáncer.¹ A su vez, datos del Instituto Nacional de Estadística y Geografía (INEGI) muestran en nuestro país que la mortalidad por esta neoplasia se ha acrecentado.⁶ Sin embargo, un estudio nacional⁷ señala que para esta neoplasia la obesidad es un factor de riesgo de menor relevancia que la diabetes, lo que es contradiciono.^{5,4}

tigación. Se evaluó la prevalencia de la obesidad, junto

Obesity, the main risk factor for endometrial cancer

ORIGINAL ARTICLE

doi: 10.5455/medarh.2014.68.19-21

Med Arh. 2014 Feb; 68(1): 19-21 Received: December 18th 2013 | Accepted: January 15th 2014 © AVICENA 2014

Metabolic Syndrome in Mexican Women Survivors of Breast Cancer: A Pilot Study at a General Hospital

Carlos Manuel Ortiz-Mendoza¹, Tania Angélica de-la-Fuente-Vera², Ernesto Pérez-Chávez²

Department of Surgery, School of Medicine, National Autonomous University of Mexico (UNAM), Mexico City¹ Department of General Surgery, Hospital General Tacuba, ISSSTE, Mexico City²


Corresponding author: Carlos Manuel Ortiz-Mendoza, MD. Servicio de Oncologia Quirúrgica, Hospital General Tacuba, ISSSTE, Lago Ontario 119, Colonia Tacuba, CP 11410, Delegación Miguel Hidalgo, México DF. Telephone and fax: (01 55) 52 65 29 49, E-mail: cortizmendozagivahoo.com.mx




Review in 3 weeks Publishing in 72 hours **Open Access**

- SN: 2165-7920
 - My actual research areas are:
 - Abnormal glucose in women survivors of breast cancer.
 - Mammography use by women affiliated to ISSSTE.
 - Novel methods on mastectomy wounds' reconstruction in obese women.
 - Retroperitoneal lymphadenectomy in endometrial cancer.
 - Obesity in women survivors of breast cancer.









Título del protocolo	Uso de la mastografía por mujeres de una clínica de mama en un hospital de segundo nivel de atención del ISSSTE.				
Palabras Claves	Cáncer de mama	Mastografía	Mujeres	Neoplasias de la Mama	Cáncer

Investigador responsable o titular			
Nombre:	Carlos Manuel Ortiz Mendoza		
Área de adscripción:	Hospital General Tacuba Cirugía General		
Correo electrónico	cortizmendoza@yahoo.com.mx		
Teléfono:	Cel. 5525269982		



Basic research interest

- Finally, I have taken part in multidisciplinary protocols with different institutions of Mexico:
- CINVESTAV
- IPN
- ISSSTE









Publishing in 72 hours



ISSN: 2165-7920

Review in 3 weeks

Journal of Clinical Case Reports Related Journals

Open Access

- Journal of Clinical Trials
- Journal of Clinical & Experimental Pathology





Review in 3 weeks

Publishing in 72 hours

Open Access

Related Conferences

 3rd International Conference and Exhibition on Clinical & Cellular Immunology (Immunology Summit-2014)